Cloderm Shortage: What Providers and Prescribers Need to Know in 2026

Clinicians who prescribe Cloderm (clocortolone pivalate 0.1% cream) are hearing more frequently from patients who can't fill their prescriptions. While there is no FDA-listed shortage of clocortolone pivalate as of 2026, several structural factors make this mid-potency topical corticosteroid genuinely difficult for patients to access. This guide provides a clinical overview of the access landscape and practical strategies to support your patients.

Current Availability Status

As of 2026, clocortolone pivalate is not on the FDA Drug Shortage Database. Brand-name Cloderm is distributed by EPI Health, LLC, and manufactured by DPT Laboratories. Generic clocortolone pivalate 0.1% cream is available from Dr. Reddy's and Prasco, providing multiple supply channels. Despite this, patient-reported difficulty filling prescriptions remains common due to:

• Low pharmacy stocking rates for this niche topical steroid
• High brand-name retail price ($350–$450 per tube)
• Insurance step therapy restrictions requiring prior authorization after failure of 2 lower-cost alternatives

Clinical Rationale for Choosing Cloderm

It's worth documenting clearly in the chart why you've chosen clocortolone pivalate over alternatives — both for clinical continuity and for any prior authorization requests. Key attributes include:

• Low allergenicity profile (Category C): No lanolin, propylene glycol, or added fragrance — important for patients with a history of contact sensitization to topical corticosteroid excipients.
• Favorable safety profile: Clinical trials demonstrated no HPA axis suppression in a 21-day study; rapid onset (Day 4) in eczema trials.
• Pediatric use: No age restriction in FDA labeling; validated in pediatric populations including infants in clinical trials.
• Facial dermatoses: Studies demonstrated safety and efficacy on the face, where many other Class 4 steroids carry additional cautions.

Navigating Insurance Step Therapy and Prior Authorization

Many commercial plans (including UnitedHealthcare's step therapy policy effective 1/1/2026) classify clocortolone pivalate as a step 2 medication in the medium-potency (Class 4) category. Patients must demonstrate failure of, or contraindication to, at least two step 1 medications before coverage is approved. Step 1 options typically include:

• Hydrocortisone butyrate 0.1% ointment
• Triamcinolone acetonide 0.1% lotion
• Prednicarbate 0.1% ointment

When submitting prior authorizations for Cloderm, document: prior corticosteroid failures/reactions, specific excipient sensitivities (propylene glycol, lanolin, fragrance allergy), the body area being treated (especially face or sensitive areas), and pediatric use where applicable.

When to Consider Alternatives

If your patient is unable to obtain Cloderm or if insurance denial is causing prolonged delay, consider:

• Mometasone furoate 0.1% cream: Class 4–5, once-daily, widely available generic, often preferred on formularies.
• Triamcinolone acetonide 0.1% cream: Universally available and inexpensive; good first bridge option.
• Tacrolimus 0.1% (Protopic): For face/intertriginous areas where long-term topical steroid use is a concern.

Helping Patients Find and Afford Cloderm

Consider directing patients to medfinder for providers — a service that contacts pharmacies near your patients to identify which ones can fill their prescription. This reduces the call burden on both your staff and the patient. Patients also benefit from GoodRx coupons that can reduce generic clocortolone pivalate costs to approximately $88.73 from a retail price of $350+.

Summary for Prescribers

Clocortolone pivalate (Cloderm) remains a clinically valuable mid-potency topical steroid, particularly for patients with excipient sensitivities or a need for facial applications. While not in a formal shortage in 2026, access barriers are real. Strong chart documentation, proactive prior authorization submissions, discount coupon guidance, and pharmacy-finding tools will serve your patients well.